CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 20, 2011

Primary Completion Date

April 23, 2020

Study Completion Date

April 23, 2020

Conditions
LymphomaB-cell Lymphoma
Interventions
PROCEDURE

Leukapheresis

"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."

PROCEDURE

Stem Cell Transplant

Stem cell infusion by vein over 30-45 minutes on Day 0

PROCEDURE

CD19-specific T Cell Infusion

T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.

DRUG

IL-2

Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.

DRUG

Carmustine

300 mg/m\^2 IV over 1 hour on Day -6

DRUG

Etoposide

200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2

DRUG

Cytarabine

200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.

DRUG

Melphalan

140 mg/m\^2 IV over 30 minutes on Day -1

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Alaunos Therapeutics

INDUSTRY

collaborator

Intrexon Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER